Biology Reference
In-Depth Information
182. Kay NE. Purine analogue-based chemotherapy regimens for
patients with previously untreated B-chronic
201. Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy-cell
leukemia with cladribine: response, toxicity, long-term follow-up.
J Clin Oncol
1997;15:1138
lymphocytic
leukemia.
Semin Hematol
2006;43:S50
e
4.
42.
202. Jehn U, Bartl R, Dietzfelbinger H, Vehling-Kaiser U, Wolf-
Hornung B, Hill W, Heinemann V. Long-term outcome of hairy
cell leukemia treated with 2-chlorodeoxyadenosine.
Ann Hematol
1999;78:139
e
183. Montserrat E. Treatment options
in chronic
lymphocytic
9.
184. Hallek M. State-of-the-art treatment of chronic lymphocytic
leukemia.
Hematology Am Soc Hematol Educ Program
; 2004;440
leukemia.
Hematol J
2004;5:S2
e
9.
185. Malspeis L, Grever MR, Staubus AE, Young D. Pharmacokinetics
of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in
cancer patients during the phase I clinical investigation of flu-
darabine phosphate.
Semin Oncol
1990;17:18
44.
203. King KM. Membrane transport of 2'-chloro-2'-deoxyadenosine
and 2-chloro-2'arabinofluoro-2'-deoxyadenosine is required for
cytotoxicity.
Proc Am Assoc Cancer Res
1994;35:A3436.
204. Griffig J, Koob R, Blakley RL. Mechanisms of inhibition of DNA
synthesis by 2-chlorodeoxyadenosine in human lymphoblastic
cells.
Cancer Res
1989;49:6923
e
e
32.
186. Fenchel K, Bergmann L, Wijermans P, et al. Clinical experience
with fludarabine and its immunosuppressive effects in pretreated
chronic lymphocytic leukemias and low-grade lymphomas.
Leuk
Lymphoma
1995;18:485
e
8.
205. Hentosh P, Koob R, Blakley RL. Incorporation of 2-halogeno-2'-
deoxyadenosine 5-triphosphates into DNA during replication by
human polymerases alpha and beta.
J Biol Chem
1990;265:4033
e
92.
187. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine
compared with chlorambucil as primary therapy for chronic
lymphocytic leukemia.
N Engl J Med
2000;343:1750
e
40.
206. Pettitt AR, Clarke AR, Cawley JC, Griffiths SD. Purine analogues
kill resting lymphocytes by p53-dependent and -independent
mechanisms.
Br J Haematol
1999;105:986
e
7.
188. Iwasaki H, Huang P, Keating MJ, et al. Differential incorporation
of araC, gemcitabine and fludarabine into replicating and
repairing DNA in proliferating human leukemia cells.
Blood
1997;
90:270
e
8.
207. Pettitt AR, Sherrington PD, Cawley JC. The effect of p53
dysfunction on purine analogue cytotoxicity in chronic lympho-
cytic leukaemia.
Br J Haematol
1999;106:1049
e
8.
189. Weiss M, Spiess T, Berman E, Kempin S. Concomitant adminis-
tration of chlorambucil limits dose intensity of fludarabine in
previously treated patients with chronic lymphocytic leukemia.
Leukemia
1994;8:1290
e
51.
208. Parker WB, Bapat AR, Shen JX, Townsend AJ, Cheng YC. Inter-
action of 2-halogenated dATP analogs (F, Cl, Br) with human
DNA polymerases, DNA primase, ribonucleotide reductase.
Mol
Pharmacol
1988;34:485
e
3.
190. Elias L, Stock-Novack D, Head DR, et al. A phase I trial of
combination fludarabine monophosphate and chlorambucil in
chronic lymphocytic leukemia: a Southwest Oncology Group
study.
Leukemia
1993;7:361
91.
209. Leoni LM, Chao Q, Cottam HB, et al. Induction of an apoptotic
program in cell-free extracts by 2-chloro-2'-deoxyadenosine 5'-
triphosphate and cytochrome c.
Proc Natl Acad Sci, USA
1988;
95:9567
e
e
5.
191. Tefferi A, Witzig TE, Reid JM, et al. Phase I study of combined 2-
chlorodeoxyadenosine and chlorambucil in chronic lymphoid
leukemia and low-grade lymphoma.
J Clin Oncol
1994;12:569
e
71.
210. Bonate PL, Arthaud L, Cantrell Jr WR, Stephenson K,
Secrist 3rd JA, Weitman S. Discovery and development of clo-
farabine: a nucleoside analogue for treating cancer.
Nat Rev Drug
Discov
2006;5:855.
211. Waud WR, Schmid SM, Montgomery JA, Secrist 3rd JA.
Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-
beta-D-
e
74.
192. Brodsky RA. High dose cyclophosphamide treatment for auto-
immune disorders.
Scientific World Journal
2002;2:1808
e
15.
193. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the flu-
darabine and cyclophosphamide combination regimen in chronic
lymphocytic leukemia.
J Clin. Oncol
2001;19:1414
e
(Cl-F-ara-A).
Nucleosides
arabinofuranosyl)adenine
20.
194.
Eichhorst BF, Busch R, Hopfinger G. German CLL Study Group.
Fludarabine plus cyclophosphamide versus fludarabine alone in
first-line therapy of younger patients with chronic lymphocytic
leukemia.
Blood
2006;107:885
e
Nucleotides Nucleic Acids
2000;19:447.
212. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-
deoxy-2-fluoro-beta-D-
arabinofuranosyl)-adenine
in human
lymphoblastoid cells.
Cancer Res
1995;55:2847.
213. Bonate PL, Craig A, Gaynon P, et al. Population pharmacokinetics
of clofarabine, a second-generation nucleoside analog, in pediatric
patients with acute leukemia.
J Clin Pharmacol
2004;44:1309
91.
195. Catovsky D, Richards S, Matutes E, et al. UK National Cancer
Research Institute (NCRI) Haematological Oncology Clinical
Studies Group; NCRI Chronic Lymphocytic Leukaemia Working
Group. Assessment of fludarabine plus cyclophosphamide for
patients with chronic lymphocytic leukaemia (the LRF CLL4
Trial): a randomised controlled trial.
Lancet
2007;370:230
e
19.
214. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside
analog, is active in pediatric patients with advanced leukemia.
Blood
2004;103:784
e
9.
215. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine
in pediatric patients with refractory or relapsed acute lympho-
blastic leukemia.
J Clin Oncol
2006;24:1917.
216. Mackey JR, Mani RS, Selner M, et al. Functional nucleoside
transporters are required for gemcitabine influx and manifesta-
tion of toxicity in cancer cell lines.
Cancer Res
1988;58:4349
e
9.
196. Yang LY, Li L, Keating MJ, et al. Arabinosyl-2-fluoroadenine
augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-
link repair.
Mol Pharmacol
1995;47:1072
e
9.
197. Li L, Keating MJ, Plunkett W, Yang LY. Fludarabine-mediated
repair inhibition of cisplatin-induced DNA lesions in human
chronic myelogenous leukemia-blast crisis K562 cells: induction
of synergistic cytotoxicity independent of reversal of apoptosis
resistance.
Mol Pharmacol
1997;52:798
e
57.
217. Bouffard DY, Lalibert´ J, Momparler RL. Kinetic studies on 2',2'-
difluorodeoxycytidine (Gemcitabine) with purified human
deoxycytidine kinase and cytidine deaminase.
Biochem Pharmacol
1993;45:1857
e
806.
198. Robertson LE, Kantarjian H, O'Brien S. Cisplatin, fludarabine and
araC (CFA): a regimen for advanced fludarabine refractory chronic
lymphocytic leukemia.
Proc Am Soc Clin Oncol
1993;12:308.
199. McLaughlin P, Hagemeister FB, Swan Jr F, et al. Phase I study of
the combination of fludarabine, mitoxantrone and dexametha-
sone in low-grade lymphoma.
J Clin Oncol
1994;12:575
e
61.
218. Owens JK, Shewach DS, Ullman B, Mitchell BS. Resistance to 1-
beta-D-arabinofuranosylcytosine in human T-lymphoblasts
mediated by mutations within the deoxycytidine kinase gene.
Cancer Res
1992;52:2389
e
93.
219. Kroep JR, van Moorsel CJ, Veerman G, et al. Role of deoxy-
cytidine kinase (dCK), thymidine kinase 2 (TK2), deoxycytidine
deaminase (dCDA) in the antitumor activity of gemcitabine
(dFdC).
Adv Exp Med Biol
1998;431:657
e
9.
200. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine,
mitoxantrone and dexamethasone: an effective new regimen for
indolent lymphoma.
J Clin Oncol
1996;14:1262
e
e
8.
e
60.
